Organization

Guohui Xu

1 clinical trial

Clinical trial

Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled Trial

Status: Recruiting, Estimated PCD: 2026-06-30